Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 1,788 shares at $15.16 ($27K) on 2022-09-08, disclosed to the SEC on 2022-09-12.
Scheduled sale ($27k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.16 | 1,100 | $17K | 61.7% |
| 2 | $15.07 | 688 | $10K | 38.3% |
| Total | $15.13 avg | 1,788 | $27K | 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |